{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:37:32Z","timestamp":1791405452338,"version":"4.3.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10689-010-9377-y","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T09:14:23Z","timestamp":1283246063000},"page":"489-493","source":"Crossref","is-referenced-by-count":30,"title":["BRCA1 and BRCA2 families and the risk of skin cancer"],"prefix":"10.1007","volume":"9","author":[{"name":"Hereditary Breast Cancer Clinical Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ophira M.","family":"Ginsburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Kim-Sing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Ghadirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,1]]},"reference":[{"key":"9377_CR1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","volume":"343","author":"D Ford","year":"1994","unstructured":"Ford D, Easton D, Bishop T, Narod S et al (1994) Risk of cancer in BRCA1 mutation carriers. Lancet 343:692\u2013695","journal-title":"Lancet"},{"key":"9377_CR2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"The Breast Cancer Linkage Consortium","year":"1999","unstructured":"The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310\u20131316","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton DF (2002) Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358\u20131365","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR4","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"M Brose","year":"2002","unstructured":"Brose M, Rebbeck T, Calzone K et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a cancer risk evaluation program. J Natl Cancer Inst 94:1365\u20131372","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0959-8049(99)00135-5","volume":"35","author":"O Johannsson","year":"1999","unstructured":"Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumors in relatives of BRCA1 and BRCA2 germ-line mutation carriers. Eur J Cancer 35:1248\u20131257","journal-title":"Eur J Cancer"},{"key":"9377_CR6","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdh474","volume":"15","author":"JL Bermejo","year":"2004","unstructured":"Bermejo JL, Hemminki K (2004) Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol 15:1834\u20131841","journal-title":"Ann Oncol"},{"key":"9377_CR7","first-page":"4259","volume":"6","author":"H Shih","year":"2000","unstructured":"Shih H, Nathanson K, Seal S, Collins N, Stratton M, Rebbeck T, Weber B (2000) BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6:4259\u20134264","journal-title":"Clin Cancer Res"},{"key":"9377_CR8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","volume":"61","author":"D Easton","year":"1997","unstructured":"Easton D, Steele L, Fields P, Ormiston W et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on Chromosome 13q12\u201313. Am J Hum Genet 61:120\u2013128","journal-title":"Am J Hum Genet"},{"key":"9377_CR9","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/302853","volume":"66","author":"R Moslehi","year":"2000","unstructured":"Moslehi R, Chu W, Karlan B et al (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259\u20131272","journal-title":"Am J Hum Genet"},{"key":"9377_CR10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"H Risch","year":"2001","unstructured":"Risch H, McLaughlin J, Cole D, Rosen B et al (2001) Prevalence of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700\u2013710","journal-title":"Am J Hum Genet"},{"key":"9377_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1025428807472","volume":"81","author":"P Aretini","year":"2003","unstructured":"Aretini P, D\u2019 Andrea E, Pasini B, Viel A et al (2003) Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat 81:71\u201379","journal-title":"Breast Cancer Res Treat"},{"key":"9377_CR12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","volume":"336","author":"J Streuwing","year":"1997","unstructured":"Streuwing J, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401\u20131408","journal-title":"N Engl J Med"},{"key":"9377_CR13","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/jnci\/86.21.1600","volume":"86","author":"DE Goldgar","year":"1994","unstructured":"Goldgar DE, Easton DF, Cannon-Albright L, Skolnick M (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600\u20131608","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR14","first-page":"3409","volume":"56","author":"D Berman","year":"1996","unstructured":"Berman D, Costalas J, Schultz D, Grana G, Daly M, Godwin A (1996) A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish and non-Jewish individuals. Cancer Res 56:3409\u20133414","journal-title":"Cancer Res"},{"key":"9377_CR15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","volume":"95","author":"S Hahn","year":"2003","unstructured":"Hahn S, Greenhalf B, Ellis I, Sina-Frey M et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214\u2013221","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR16","first-page":"3789","volume":"62","author":"K Murphy","year":"2002","unstructured":"Murphy K, Brune K, Griffin C, Sollenberger J et al (2002) Evaluation of candidate genes MPP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789\u20133793","journal-title":"Cancer Res"},{"key":"9377_CR17","first-page":"409","volume":"60","author":"G Lal","year":"2000","unstructured":"Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1 and BRCA2 mutations. Cancer Res 60:409\u2013416","journal-title":"Cancer Res"},{"key":"9377_CR18","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-03-0604","volume":"10","author":"T Kirchhoff","year":"2004","unstructured":"Kirchhoff T, Kauff N, Mitra N et al (2004) BRCA mutations and the risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10:2918\u20132921","journal-title":"Clin Cancer Res"},{"key":"9377_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/345310","volume":"72","author":"SM Edwards","year":"2003","unstructured":"Edwards SM, Kote-Jarai Z, Meitz J et al (2003) Two percent of men with early onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1\u201312","journal-title":"Am J Hum Genet"},{"key":"9377_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1054\/bjoc.2000.1249","volume":"83","author":"A Vazina","year":"2000","unstructured":"Vazina A, Baniel J, Shtriker A et al (2000) The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 83:463\u2013466","journal-title":"Br J Cancer"},{"key":"9377_CR21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1086\/302525","volume":"65","author":"A Hubert","year":"1999","unstructured":"Hubert A, Peretz T, Manor O et al (1999) The Jewish Ashkenazi founder mutations in the BRCA1\/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921\u2013924","journal-title":"Am J Hum Genet"},{"key":"9377_CR22","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(98)03300-5","volume":"352","author":"S Thorlacius","year":"1998","unstructured":"Thorlacius S, Struewing J, Hartge P et al (1998) Population based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337\u20131339","journal-title":"Lancet"},{"key":"9377_CR23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s001090050162","volume":"75","author":"S Sigurdsson","year":"1997","unstructured":"Sigurdsson S, Thorlaciaus S, Tomasson J et al (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75:758\u2013761","journal-title":"J Mol Med"},{"key":"9377_CR24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ijc.10155","volume":"98","author":"J Iscovich","year":"2002","unstructured":"Iscovich J, Abdulrazik M, Cour C et al (2002) Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int J Cancer 98:42\u201344","journal-title":"Int J Cancer"},{"key":"9377_CR25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ijc.10693","volume":"102","author":"R Scott","year":"2002","unstructured":"Scott R, Vajdic C, Armstrong B et al (2002) BRCA2 mutations in a population based series of patients with ocular melanoma. Int J Cancer 102:188\u2013191","journal-title":"Int J Cancer"},{"key":"9377_CR26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jnci\/djh008","volume":"96","author":"B Niell","year":"2004","unstructured":"Niell B, Rennert G, Bonner J, Almog R, Tomsho L, Gruber S (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15\u201321","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jnci\/djh006","volume":"96","author":"T Kirchhoff","year":"2004","unstructured":"Kirchhoff T, Satagopan J, Kauff N et al (2004) Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 96:68\u201370","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1054\/bjoc.2000.1598","volume":"84","author":"R Chen-Stoyerman","year":"2001","unstructured":"Chen-Stoyerman R, Figer A, Fidder H et al (2001) The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. Br J Cancer 84:475\u2013477","journal-title":"Br J Cancer"},{"key":"9377_CR29","first-page":"559","volume":"20","author":"L Drucker","year":"2000","unstructured":"Drucker L, Stackievitz R, Shpitz B, Yarkoni S (2000) Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. Anticancer Res 20:559\u2013561","journal-title":"Anticancer Res"},{"key":"9377_CR30","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/94.16.1221","volume":"94","author":"CB Begg","year":"2002","unstructured":"Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221\u20131226","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jnci\/95.1.74","volume":"95","author":"CR Amos","year":"2003","unstructured":"Amos CR (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:74\u201375","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jnci\/95.1.73-a","volume":"95","author":"H Risch","year":"2003","unstructured":"Risch H, Narod S (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:73\u201374","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jnci\/95.1.75","volume":"95","author":"PP Pharoah","year":"2003","unstructured":"Pharoah PP, Antoniou A, Hopper J, Easton D (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:75\u201376","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jnci\/95.1.76","volume":"95","author":"AS Whittemore","year":"2003","unstructured":"Whittemore AS, Gong G (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:76\u201377","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jnci\/95.1.78","volume":"95","author":"W Burke","year":"2003","unstructured":"Burke W, Austin MA (2003) Re: on the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 95:78\u201379","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR36","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1126\/science.306.5705.2187c","volume":"306","author":"DF Easton","year":"2004","unstructured":"Easton DF, Hopper JL, Thomas DL, Antoniou A, Pharoah PDP, Whittemore AS (2004) Re: breast cancer risks for BRCA1\/2 carriers. Science 306:2187\u20132188","journal-title":"Science"},{"key":"9377_CR37","first-page":"2188","volume":"306","author":"S Wacholder","year":"2004","unstructured":"Wacholder S, Struewing JP, Hartage P, Greene MH, Tucker MA (2004) Re: breast cancer risks for BRCA1\/2 carriers. Science 306:2188","journal-title":"Science"},{"key":"9377_CR38","first-page":"2188","volume":"306","author":"MC King","year":"2004","unstructured":"King MC, New York Breast Cancer Study Group (2004) Re: breast cancer risks for BRCA1\/2 carriers. Science 306:2188\u20132191","journal-title":"Science"},{"issue":"23","key":"9377_CR39","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/jnci\/djj500","volume":"98","author":"K Offit","year":"2006","unstructured":"Offit K (2006) BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 98(23):1675\u20131677","journal-title":"J Natl Cancer Inst"},{"key":"9377_CR40","first-page":"256","volume":"56","author":"DR Easton","year":"1995","unstructured":"Easton DR, Ford D, Bishop DT (1995) Breast and ovarian incidence in BRCA1-mutartion carriers. Am J Hum Genet 56:256\u2013271","journal-title":"Am J Hum Genet"},{"key":"9377_CR41","doi-asserted-by":"crossref","first-page":"R175","DOI":"10.1186\/bcr632","volume":"5","author":"N Loman","year":"2003","unstructured":"Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H (2003) Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 5:R175\u2013R186","journal-title":"Breast Cancer Res"},{"key":"9377_CR42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0190-9622(08)81509-5","volume":"30","author":"DL Miller","year":"1994","unstructured":"Miller DL, Weinstock MA (1994) Nonmelanoma skin cancer in the United States: incidence. J Am Acad Derm 30:774\u2013778","journal-title":"J Am Acad Derm"},{"key":"9377_CR43","unstructured":"SEER 17 (2000\u20132006). http:\/\/seer.cancer.gov"},{"key":"9377_CR44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","volume":"96","author":"E Levy-Lahad","year":"2007","unstructured":"Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 carriers: minireview. British J Cancer 96:11\u201315","journal-title":"British J Cancer"},{"key":"9377_CR45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ijc.10155","volume":"98","author":"J Iscovitch","year":"2002","unstructured":"Iscovitch J, Abdulrazik M, Cour C et al (2002) Prevalence of the BRCA2 6174delT mutation in uveal melanoma patients. Int J Cancer 98:42\u201344","journal-title":"Int J Cancer"},{"key":"9377_CR46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10689-008-9206-8","volume":"8","author":"L Kadouri","year":"2009","unstructured":"Kadouri L, Temper M, Grenader T, Abeliovich D, Hamburger T, Peretz T, Lotem M (2009) Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer 8:29\u201332","journal-title":"Fam Cancer"},{"key":"9377_CR47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10689-007-9143-y","volume":"6","author":"C Monerrat","year":"2007","unstructured":"Monerrat C, Chompret A, Kannengiesser C, Avril M-F et al (2007) BRCA1, BRCA2, CDKN2a germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer 6:453\u2013461","journal-title":"Fam Cancer"},{"key":"9377_CR48","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4161\/cbt.4.12.2378","volume":"4","author":"A Navaraj","year":"2005","unstructured":"Navaraj A, Mori T, El-Deiry WS (2005) Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biol Ther 4:1409\u20131414","journal-title":"Cancer Biol Ther"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-010-9377-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-010-9377-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-010-9377-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T21:46:04Z","timestamp":1559252764000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-010-9377-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["9377"],"URL":"https:\/\/doi.org\/10.1007\/s10689-010-9377-y","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}